Long-term Immune Protection in COVID-19 Patients
Networks
-
Datasets
-
Variables
-
The overall goal of the study is to identify the mechanism of response of our immune system to the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
The specific objectives are to:
* Test patients' ability to neutralize the SARS-CoV-2 by measuring circulating antibodies;
* Study memory immune cells that offer long-term protection; and
* Compare the short and long-term immune responses to SARS-CoV-2 infection and vaccination.
- Start Year
- 2020
| Investigators | Contacts |
|---|---|
|
|
Design
- Study design
- Cohort
- Follow Up
- For the COVID-19 positive and negative cohorts, paticipant's antibodies are tested approximately 14 days after the onset of symptoms (baseline), 6 months and 1 year later. For the COVID-19 vaccinated cohort, antibody testing will be conducted up to 5 times: baseline (pre-vaccination), 3 weeks after first vacinnation, 3 weeks after second vaccination, 6 months and 12 months post-vaccination.
Recruitment
- Recruitment Target
-
- Individuals
Number of Participants
- Number of Participants
- 600
- Number of Participants with Biological Samples
- 600
- Supplementary Information
-
COVID-19 positive cohort planned to be conducted on approximately 200 patients
COVID-19 negative cohort planned to be conducted on approximately 200 patients
COVID-19 vaccinated cohort planned to be conducted on approximately 200 non-infected participants
Access
Availability of data and biosamples
| Possible Access to Data | |
| Possible Access to Biosamples | |
| Other |
Timeline
Populations
The population is composed of patients who recovered from COVID-19 infection in Hamilton, Ontario, Canada and who were tested as positive from the reverse transcriptase polymerase chain reaction (RT-PCR) test.
Selection Criteria
- Newborns
- Twins
- Countries
-
- Canada
- Territory
- Hamilton
- Ethnic Origin
-
- Health Status
-
- Recovered from COVID-19 infection
- Other Criteria
- Tested as positive from the reverse transcriptase polymerase chain reaction (RT-PCR) test
Recruitment
- Sources of recruitment
-
- Specific population
- Specific Population
-
- Clinic patients
- Supplementary Information
-
Study participants were recruited from patients who recovered from COVID-19 infection and were initially identified by treating physicians, Public Health and through hospital discharge databases that include hospitals in Hamilton, Ontario, Canada (Hamilton General Hospital, Juravinski Hospital, McMaster University Medical Centre, and St. Joseph’s Healthcare).
Number of Participants
- Number of Participants
- 200
- Number of Participants with Biological Samples
- 200
Data Collection Events
| # | Name | Description | Start | End |
|---|---|---|---|---|
| 0 |
LIPiC - Positive Cohort - Baseline
|
COVID-19 antibody detection was performed using an in-house enzyme-linked immunosorbent assay (ELISA) on blood samples. | 2020-09 | |
| 1 |
LIPiC - Positive Cohort - Follow-up 1
|
COVID-19 antibody detection was performed using an in-house enzyme-linked immunosorbent assay (ELISA) on blood samples. | 2021-03 | |
| 2 |
LIPiC - Positive Cohort - Follow-up 2
|
COVID-19 antibody detection was performed using an in-house enzyme-linked immunosorbent assay (ELISA) on blood samples. | 2021-09 |
The population is composed of patients who recovered from COVID-19 infection in Hamilton, Ontario, Canada and who were tested as negative from the reverse transcriptase polymerase chain reaction (RT-PCR) test.
Selection Criteria
- Newborns
- Twins
- Countries
-
- Canada
- Territory
- Hamilton
- Ethnic Origin
-
- Health Status
-
- Recovered from COVID-19 infection
- Other Criteria
- Tested as negative from the reverse transcriptase polymerase chain reaction (RT-PCR) test
Recruitment
- Sources of recruitment
-
- Specific population
- Specific Population
-
- Clinic patients
- Supplementary Information
-
Study participants were recruited from patients who recovered from COVID-19 infection and were initially identified by treating physicians, Public Health and through hospital discharge databases that include hospitals in Hamilton, Ontario, Canada (Hamilton General Hospital, Juravinski Hospital, McMaster University Medical Centre, and St. Joseph’s Healthcare).
Number of Participants
- Number of Participants
- 200
- Number of Participants with Biological Samples
- 200
Data Collection Events
| # | Name | Description | Start | End |
|---|---|---|---|---|
| 0 |
LIPiC - Negative Cohort - Baseline
|
COVID-19 antibody detection was performed using an in-house enzyme-linked immunosorbent assay (ELISA) on blood samples. | 2020-09 | |
| 1 |
LIPiC - Negative Cohort - Follow-up 1
|
COVID-19 antibody detection was performed using an in-house enzyme-linked immunosorbent assay (ELISA) on blood samples. | 2021-03 | |
| 2 |
LIPiC - Negative Cohort - Follow-up 2
|
COVID-19 antibody detection was performed using an in-house enzyme-linked immunosorbent assay (ELISA) on blood samples. | 2021-09 |
The population is composed of non-infected individuals who are planning to be vaccinated with the vaccines against SARS-CoV-2.
Selection Criteria
- Newborns
- Twins
- Countries
-
- Canada
- Territory
- Hamilton
- Ethnic Origin
-
- Health Status
-
- Non-infected with COVID-19
- Other Criteria
- Planning to be vaccinated with vaccines against SARS-CoV-2
Recruitment
- Sources of recruitment
-
- General population
- General Population
-
- Selected sample
Number of Participants
- Number of Participants
- 200
- Number of Participants with Biological Samples
- 200
Data Collection Events
| # | Name | Description | Start | End |
|---|---|---|---|---|
| 0 |
LIPiC - Vaccinated Cohort - Baseline
|
COVID-19 antibody detection was performed using an in-house enzyme-linked immunosorbent assay (ELISA) on blood samples. | 2021-03 | |
| 1 |
LIPiC - Vaccinated Cohort - 3 weeks post-vaccination 1
|
Three weeks after first vaccination, COVID-19 antibody detection was performed using an in-house enzyme-linked immunosorbent assay (ELISA) on blood samples. | 2021-04 | |
| 2 |
LIPiC - Vaccinated Cohort - 3 weeks post-vaccination 2
|
Three weeks after second vaccination, COVID-19 antibody detection was performed using an in-house enzyme-linked immunosorbent assay (ELISA) on blood samples. | 2021-05 | |
| 3 |
LIPiC - Vaccinated Cohort - 6 months post-vaccination
|
Six months after the vaccination, COVID-19 antibody detection was performed using an in-house enzyme-linked immunosorbent assay (ELISA) on blood samples. | 2021-09 | |
| 4 |
LIPiC - Vaccinated Cohort - 12 months post-vaccination
|
Twelve months after the vaccination, COVID-19 antibody detection was performed using an in-house enzyme-linked immunosorbent assay (ELISA) on blood samples. | 2022-03 |
Classifications
- Socio-demographic and economic characteristics
- Lifestyle and behaviours
- Birth, pregnancy and reproductive health history
- Perception of health, quality of life, development and functional limitations
- Diseases
- Symptoms and signs
- Medication and supplements
- Non-pharmacological interventions
- Health and community care services utilization
- Death
- Physical measures and assessments
- Laboratory measures
- Cognition, personality and psychological measures and assessments
- Life events, life plans, beliefs and values
- Preschool, school and work life
- Social environment and relationships
- Physical environment
- Administrative information
Socio-demographic and economic characteristics
Age/birthdate
Sex/gender
Symptoms and signs
Symptoms related to multiple categories
Non-pharmacological interventions
Laboratory diagnosis interventions
Health and community care services utilization
Hospitalizations